Developing Realistic Pathways in Cost-Effectiveness Models for Psoriasis: What to Do When a Biologic Fails

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.1627
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

What Does It Take to Survive a Breach in Today’s High- Risk World? When Your Prevention Fails (And It’s Going to Fail), What Do You Do?

Pittsburgh Journal of Technology Law and Policy
2014English

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-To-Severe Psoriasis in the United States

Dermatology and Therapy
Dermatology
2018English

Prm130 - Open-Source Software for Developing Computationally Efficient Cost-Effectiveness Models to Evaluate Sequential Treatment Strategies in Oncology

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

What to Do When Complications Occur

Anaesthesia
AnesthesiologyPain Medicine
2018English

What to Do When Disaster Strikes

Serials Librarian
LibraryInformation Sciences
2003English

“Do We Have to Replace the Balloon Pump When It Fails?”

Hastings Center Report
Health PolicyPhilosophyLegal AspectsHealthEthicsIssues
2020English

951 Serum Leucine-Rich-Α-2 Glycoprotein Is a Biomarker for the Effectiveness of Biologic Therapies in Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2018English

Algorithm for Selecting Ideal Biologic Treatment for Psoriasis

Journal of Clinical & Experimental Dermatology Research
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy